FDA Approves BIZENGRI® for NRG1+ Cancer Therapy
The FDA has approved BIZENGRI® (zenocutuzumab-zbco), the first therapy specifically targeting neuregulin 1 (NRG1) gene fusions in advanced unresectable or
Read MoreThe FDA has approved BIZENGRI® (zenocutuzumab-zbco), the first therapy specifically targeting neuregulin 1 (NRG1) gene fusions in advanced unresectable or
Read More